HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice.

Abstract
The platelet P2Y(1) ADP receptor is an attractive target for new antiplatelet drugs. However, because of the lack of strong and stable antagonists, only a few studies have suggested that pharmacological inhibition of the P2Y(1) receptor could efficiently inhibit experimental thrombosis in vivo. Our aim was to determine whether the newly described potent and selective P2Y(1) receptor antagonist MRS2500 [2-iodo-N(6)-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate] could inhibit platelet function ex vivo and experimental thrombosis in mice in vivo. MRS2500 was injected intravenously into mice, and its effect on ex vivo platelet aggregation and in several models of thrombosis in vivo was determined. MRS2500 displayed high potency and stable and selective P2Y(1) receptor inhibition ex vivo. Although MRS2500 injection resulted in only moderate prolongation of the bleeding time, it provided strong protection in systemic thromboembolism induced by infusion of a mixture of collagen and adrenaline. MRS2500 also potently inhibited localized arterial thrombosis in a model of laser-induced vessel wall injury with two degrees of severity. Moreover, combination of MRS2500 with clopidogrel, the irreversible inhibitor of the platelet P2Y(12) receptor for ADP, led to increased antithrombotic efficacy compared with each alone. These results add further evidence for a role of the P2Y(1) receptor in thrombosis and validate the concept that targeting the P2Y(1) receptor could be a relevant alternative or complement to current antiplatelet strategies.
AuthorsBéatrice Hechler, Christelle Nonne, Eun Joo Roh, Marco Cattaneo, Jean-Pierre Cazenave, François Lanza, Kenneth A Jacobson, Christian Gachet
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 316 Issue 2 Pg. 556-63 (Feb 2006) ISSN: 0022-3565 [Print] United States
PMID16236815 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 2-iodo-N(6)-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate
  • Deoxyadenine Nucleotides
  • P2ry1 protein, mouse
  • Platelet Aggregation Inhibitors
  • Purinergic P2 Receptor Antagonists
  • Receptors, Purinergic P2
  • Receptors, Purinergic P2Y1
Topics
  • Animals
  • Blood Platelets (drug effects, metabolism)
  • Deoxyadenine Nucleotides (pharmacology, therapeutic use)
  • Disease Models, Animal
  • Male
  • Mice
  • Mice, Knockout
  • Platelet Aggregation (drug effects)
  • Platelet Aggregation Inhibitors (pharmacokinetics, therapeutic use)
  • Purinergic P2 Receptor Antagonists
  • Receptors, Purinergic P2 (genetics)
  • Receptors, Purinergic P2Y1
  • Thromboembolism (blood, drug therapy, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: